Drug Profile
Amlodipine/telmisartan - Boehringer Ingelheim
Alternative Names: Amlodipine besylate/telmisartan; Micamlo Combination Tablets; Micardis Amlo; Micardis Anlo; Onduarp; Telmisartan/amlodipine; Telmisartan/amlodipine besylate; TwynstaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Astellas Pharma; Boehringer Ingelheim; Yuhan
- Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Small molecules
- Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 30 Oct 2020 Astellas Pharma terminates its sales agreement for the Micardis family, prior to October 2020
- 17 Sep 2020 Discontinued - Phase-III for Hypertension (Combination therapy, Treatment-experienced) in Japan (PO) (Boehringer Ingelheim pipeline, September 2020)
- 18 Dec 2017 Chemical structure information added